2023-506713-22-00招募中2 期
An open-label sleep laboratory study of efficacy and safety of piromelatine in a well-defined population of patients with idiopathic (isolated) Rapid Eye Movement Behavior Disorder (iRBD).
Neurim Pharmaceuticals (1991) Ltd., Neurim Pharmaceuticals (1991) Ltd.1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2024年1月29日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- iRBD severity assessed by vPSG performed according to the AASM recommendations, with the addition of electromyography of both FDS muscles in the upper limbs (optional according to the AASM recommendations) and scored by a composite measure of motor events, iRBD episodes, and vocalizations frequency and severity as recommended by the IRBDSG
研究概览
简要总结
Assess the efficacy and safety of short-term (6 weeks) treatment with piromelatine as compared to baseline measures.
研究设计
- 分配方式
- Not Applicable
- 主要目的
- Study Design
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •The participant must understand the study procedures and agree to participate by providing written informed consent.
- •The participant must be willing and able to comply with all trial procedures and restrictions.
- •Male or female adult participants aged 50 to 70 years diagnosed with iRBD based on the criteria established by the ICSD-3 and confirmed by vPSG.
- •PSG demonstrates that the participant does not have other comorbid sleep disorders or clinically significant nocturnal hypoxemia (O2 saturation ≤90% for ≥5% of total sleep time) and that their apnea-hypopnea index (AHI) is ≤
- •Permitted medications (those that are not prohibited medications) must be on stable dose for 3 months.
- •Body mass index (BMI) between 18 and 32 kg/m2 , inclusive.
- •Normal physical examination findings, vital signs, clinical laboratory test results, and electrocardiogram (ECG) results or abnormal results that are judged not clinically significant by the Investigator.
排除标准
- •Any contraindication to perform [CCI], such as participants who are treated with psychotropic drugs, anti-Parkinson’s Disease(PD) drugs and drugs that may interfere with [CCI] will be excluded.
- •Has a usual bedtime later than 01:00 or an occupation requiring night-time shift work or variable shift work within the past 6 months or travel with significant jet lag within 14 days before baseline.
- •Female patients who meet the following criteria: a. Pregnant, breastfeeding, and/or planning to become pregnant and/or breastfeed during the study; b. Is not at least 1 year postmenopausal or surgically sterile (tubal ligation, tubal occlusion, bilateral oophorectomy, or hysterectomy).
- •Males who are fertile but refuse to practice double-barrier methods of contraception with female partners of childbearing potential, starting from the signing of the ICF until 30 days after the last dose of the trial medication.
- •Any concurrent medical condition that, in the judgment of the Investigator, might interfere with the conduct of the study, confound the interpretation of the study results, or endanger the patient’s well-being.
- •Current or past history of schizophrenia, schizoaffective disorder or any other form of psychotic disorder, obsessive compulsive disorder, personality disorders, bipolar disorder, PTSD or any other significant disorder as assessed by the Investigator.
- •Currently meets Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) for major depressive disorder and has required initiation of medication or hospitalization within the previous 90 days.
- •Significant suicide risk as defined by (1) suicidal ideation as endorsed on items 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS) within the past year, during Screening or at baseline, or during the study; (2) suicidal behaviors within the past year.
- •Current (within the last year) alcohol or substance use disorder.
- •Positive urine drug screen for benzodiazepines, opioids, and/or illicit drugs or drugs of abuse at Screening and/or baseline. Potential participants who test positive for opioids in urine drug testing need not be excluded if in the clinical opinion of the Investigator, this is due to the participant taking prior/concomitant medications containing opioids for a medical condition and not due to drug abuse.
- •Any cardiovascular disease that is clinically significant, unstable, or decompensated. Additionally, patients with any of the following conditions are excluded from participation in the study: a. History of congenital QTc prolongation or presence of QTc prolongation (QTcF >450msec for men and QTcF >470 msec for women on Screening ECG); b. Second-degree (if Mobitz II) or third-degree atrioventricular block; c. History (≤1 year before Visit 1) of clinically manifest ischemic heart disease including myocardial infarction, stable or unstable angina, coronary arteriography, or cardiac stress testing/imaging with findings consistent with coronary occlusion or infarction; d. Heart rate on supine vital sign measurement of <50bpm or >120bpm or any heart rate that is clinically symptomatic; e. Premature ventricular contractions associated with clinical symptoms and/or any complex premature ventricular contractions; f. Atrial fibrillation or flutter that is symptomatic or associated with uncontrolled heart rate or hemodynamic instability, requires anticoagulation, or is of recent (<12 months) or unknown onset; g. Systolic blood pressure >160 mmHg OR diastolic blood pressure >95 mmHg on 3 separate determinations 5 minutes apart, taken at same arm, after the participant feels comfortable and relaxed at the research facility; h. Clinically significant orthostatic hypotension.
- •Participants with narcolepsy type 1 (narcolepsy with cataplexy), and the pathogenesis (orexin deficiency), hypersomnia, excessive daytime sleepiness, has moderate or severe obstructive sleep apnea (OSA, AHI >15) or moderate to severe restless leg syndrome (RLS, IRLS scale >10) diagnosed by previous PSG or interview at Screening.
- •Gastric bypass or any condition that would be expected to affect drug absorption (gastric banding procedures are acceptable if not associated with absorption problems).
- •Positive test for hepatitis B surface antigen and/or hepatitis B core antibody immunoglobulin M at Screening.
- •Positive hepatitis C antibody at Screening (Visit 1), with the exception of patients for whom the reflex HCV RNA test is negative.
- •The participant has abnormal laboratory values or clinical findings at the Screening Visit or during the evaluation of eligibility for the Long-term Extension Treatment (reviewed at Visit 4 using safety laboratory results from Visit 3) that are judged to be clinically significant including, but not limited to: a. Alanine aminotransferase and/or aspartate aminotransferase >3 × the upper limit of normal (ULN); b. Total bilirubin >3 × ULN; c. eGFR <50; d. Any other clinically significant abnormal laboratory result obtained at the Screening Visit or during the evaluation of eligibility for the Long-term Extension Treatment (reviewed at Visit 4 using safety laboratory results from Visit 3).
- •Any other clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal or any other major concurrent illness that, in the opinion of the Investigator, may interfere with the interpretation of the study results or constitute a health risk for the participant if they take part in the study in the opinion of the Investigator, trial Physician or designee.
- •Hypersensitivity to the trial medication or any of the excipients.
- •Treatment with any investigational product within 30 days (or at least 5 half-lives, whichever is longer) before Visit
- •Unable or unlikely to comply with the study protocol or is unsuitable for any other reason, as judged by the Investigator.
- •Selective serotonin reuptake inhibitors and benzodiazepine hypnotics are prohibited in the study and up to 3 months before Screening as these medications may worsen or provoke iRBD symptoms.
- •Use of Cyp3A inhibitors, melatonin, and beta blockers, are prohibited in the study and up to 2 weeks before Screening.
- •Participants who are treated with psychotropic drugs, anti-PD medications and medications that may interfere with [CCI] will be excluded.
- •Diagnosis of alpha-synuclein pathology, such as PD, multiple system atrophy, and dementia with Lewy bodies suspected or confirmed by neurological examination, diagnosed according to current international criteria.
- •Diagnosis of non-synuclein neurodegenerative disorders as progressive supranuclear palsy, frontotemporal dementia, amyotrophic lateral sclerosis, AD, spinal cerebellar ataxia type 3, Huntington disease, and myotonic dystrophy type
- •Cognitive impairment as determined by the Montreal Cognitive Assessment (MoCA) score of ≤
- •History of seizure disorder, stroke, significant head injury, tumor of the central nervous system, or any other condition that can cause structural lesions in the brainstem due to vascular, demyelinating, neoplastic, and traumatic etiologies.
结局指标
主要结局
iRBD severity assessed by vPSG performed according to the AASM recommendations, with the addition of electromyography of both FDS muscles in the upper limbs (optional according to the AASM recommendations) and scored by a composite measure of motor events, iRBD episodes, and vocalizations frequency and severity as recommended by the IRBDSG
iRBD severity assessed by vPSG performed according to the AASM recommendations, with the addition of electromyography of both FDS muscles in the upper limbs (optional according to the AASM recommendations) and scored by a composite measure of motor events, iRBD episodes, and vocalizations frequency and severity as recommended by the IRBDSG
RSWA quantified in the chin (phasic, tonic, and any muscle activity) and in the FDS (phasic muscle activity) on 3-second mini-epochs (manually identified) according to the [CCI], using a validated algorithm, with manual artifact correction after automatic analysis
RSWA quantified in the chin (phasic, tonic, and any muscle activity) and in the FDS (phasic muscle activity) on 3-second mini-epochs (manually identified) according to the [CCI], using a validated algorithm, with manual artifact correction after automatic analysis
[CCI]
[CCI]
Sleep hypnographic variables (SL, WASO, TST, SE, % of N1, N2, N3 and REM sleep) scored in accordance with the AASM
Sleep hypnographic variables (SL, WASO, TST, SE, % of N1, N2, N3 and REM sleep) scored in accordance with the AASM
EEG power spectral analysis during REM/NREM sleep
EEG power spectral analysis during REM/NREM sleep
PSQI score
PSQI score
ESS score
ESS score
Relationship between response/no response and the presence of [CCI]. For that reason, blood samples of all enrolled patients will undergo [CCI].
Relationship between response/no response and the presence of [CCI]. For that reason, blood samples of all enrolled patients will undergo [CCI].
Safety parameters (vital signs, physical examination, AEs, SAEs, laboratory assessments, and ECG)
Safety parameters (vital signs, physical examination, AEs, SAEs, laboratory assessments, and ECG)
次要结局
- iRBD severity assessed by vPSG with the addition of electromyography of both FDS muscles in the upper limbs (optional according to the AASM recommendations)
- RSWA quantified in the chin (phasic, tonic, and any muscle activity) and in the FDS (phasic muscle activity)
- [CCI]
- Sleep hypnographic variables (SL, WASO, TST, SE)
- PSQI score
- ESS score
- EEG power spectral analysis during REM/NREM sleep
- MoCA
- Safety parameters (vital signs, physical examination, AEs, SAEs, laboratory assessments, and ECG)
研究者
Prof. Nava Zisapel
Scientific
Neurim Pharmaceuticals (1991) Ltd.
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)Ulcerative ColitisNCT07265570InSilico Medicine Hong Kong Limited80
已完成
1 期
A Study of HS-10518 in Healthy Adult Premenopausal Females in ChinaNCT07264192West China Second University Hospital60
招募中
3 期
Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor DeficiencyNCT07266805Pharvaris Netherlands B.V.32
招募中
3 期
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)Cold UrticariaNCT07266402Celldex Therapeutics240
已完成
1 期
Randomized, double-blind, placebo-controlled study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of pitolisant after repeated oral ascending doses for 14 days, including the pitolisant effect on cardiac repolarization in healthy volunteers.2023-503945-78-00Bioprojet Pharma75